Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma

Acta Oncol. 2020 Dec;59(12):1547-1551. doi: 10.1080/0284186X.2020.1821913. Epub 2020 Sep 24.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Alemtuzumab / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic
  • Epigenesis, Genetic
  • Humans
  • Leukemia, Prolymphocytic*
  • Leukemia, Prolymphocytic, T-Cell* / genetics
  • Lymphoma*
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma*
  • Sulfonamides
  • T-Lymphocytes

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • Alemtuzumab
  • venetoclax